Early IBD results from Spyre Therapeutics Spyre Therapeutics reported that its inflammatory bowel disease (IBD) treatment succeeded in its first major test in an early clinical trial, positioning the company to compete with larger drugmakers. The update signals that the program has generated…
Continue reading...
Continue reading...